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A B S T R A C T
Background: The principal target age for Australian BreastScreen services was 50–69 years in 1991–2013 and
50–74 years from 2014. History of BreastScreen NSW screening participation of NSW women diagnosed with
breast cancer in 2005–2014 was examined using linked BreastScreen and Cancer Registry data.
Methods: Differences in BreastScreen participation were investigated by sociodemographic and tumour char-
acteristics, and diagnostic period, using the Pearson Chi-square test, or Fisher’s Exact test when numbers were
small, and by multivariate logistic regression.
Results: At breast cancer diagnosis, a history of BreastScreen participation varied by age from 23 % for
40−49 years to 68 % for 50–59 years, 72 % for 70–74 years and 78 % for 60–69 years. Among women ex-
periencing breast cancer at age 50–69 years, 60 % had participated in BreastScreen< 24 months of diagnosis.
Higher odds of BreastScreen participation applied to residents of inner regional and remote compared with
major city areas and for women with localized compared with more distant cancer spread. BreastScreen parti-
cipation was lower in Indigenous than non-Indigenous women. Differences in participation existed by country of
birth and residential location, but they were not pronounced.
Conclusion: The history of BreastScreen NSW participation of 60 %<24 months for women aged 50–69 years at
breast-cancer diagnosis is less than the 70 % target for biennial screening coverage at a population level, but this
target has never been reached by an Australian jurisdiction. Qualitative research of screening barriers and op-
portunities may provide a useful guide for reducing barriers across the population.
1. Introduction
BreastScreen NSW was launched as a population-based screening
program in 1991, with a principal target age range of 50–69 years and
screening eligibility from the age of 40 years [1,2]. From 2014, the
principal age target was extended to include 50–74 years.
The accreditation standard for population coverage by biennial
BreastScreen screening is 70 % for the 50–69-year target age range,
although this has never been achieved at a national or jurisdictional
level [1]. The standard covers all women, including Indigenous
(Aboriginal and Torres Strait Islander) women, the culturally and lin-
guistically diverse, and women from the more disadvantaged and
geographically remote areas [1]. The aim of BreastScreen is to reduce
breast cancer mortality and morbidity to levels equivalent to, or better
than, that observed in the initial field trials, and to do so equitably
across population sub-groups [1,3].
There is much debate about screening policy and discussion around
taking a risk-based approach to all screening programs. Whatever the
approach, monitoring and evaluating implementation would be an
important component. BreastScreen can only affect breast cancer out-
comes to the extent that women participate.
We linked BreastScreen NSW and NSW Cancer Registry data in this
study to determine screening participation histories of women diag-
nosed with invasive breast cancers, including whether they had been
screened in the 24 months preceding diagnosis [1]. This duration ac-
cords with the biennial BreastScreen screening standard at a population
level although an interval of up to 27 months is allowed between
screening rounds in national accreditation [1]. We selected 24 months
in this study to determine whether BreastScreen participation, as
measured in this study, appeared to be accurate (i.e., whether it was
associated with expected differences in cancer stage).
An additional aim was to determine differences in a history of
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screening of diagnosed women by age, country of birth, Indigenous
status, and place of residence classified by geographic remoteness and
socio-economic disadvantage, to assist targeting of public education on
screening. These data, by relating to women diagnosed with breast
cancer, are complementary to population-based data. Among these di-
agnosed women would be some at elevated risk of breast cancer mor-
tality.
Data for this project were obtained from BreastScreen NSW, and
from the NSW Cancer Registry which operates under legal mandate
through the NSW Public Health Act 2010. BreastScreen NSW and the
Registry are both administered by Cancer Institute NSW under the
Cancer Institute (NSW) Act 2013. The Cancer Institute is the NSW
Government agency responsible for cancer monitoring in NSW and for
providing data support for service planning and administration.
2. Methods
Principal data sources were BreastScreen NSW attendance records
and the NSW Cancer Registry. The Registry receives cancer notifica-
tions under legal mandate from hospitals, diagnostic laboratories and
ancillary sources for all cancers except basal and squamous cell carci-
nomas of the skin [4]. The Registry records: (a) demographic de-
scriptors, including age at diagnosis, country of birth, Indigenous
status, and residential address (used to determine local health district
and geographic area of residence by remoteness and socio-economic
disadvantage); and (b) stage at diagnosis (localized, regional or distant)
for invasive female breast neoplasms (ICD-O-3 topography code: C50)
[4–6].
All invasive female breast cancers recorded by the NSW Cancer
Registry with a diagnosis during 2005–2014, and occurring in women
aged 40–74 years, were included. Extracts of Registry and BreastScreen
attendance data were linked by the Centre for Health Record Linkage in
accordance with the principle of separating person-identified and con-
tent data to protect privacy [7].
Based on BreastScreen NSW records, women with breast cancer
were classified as: (1) not having participated in the BreastScreen NSW
program since program inception in 1991; (2) having participated but
not in the 24 months immediately preceding their breast cancer diag-
nosis; and (3) having participated in that 24-month period.
Descriptors used in the analyses were: (a) age at diagnosis classified
as 40–49, 50–59, 60–69 or 70–74 years; (b) diagnostic period classified
as 2005–2009 or 2010–2014; (c) country of birth broadly classified by
country/region using the Standard Australia Classification of Countries;
[8] (d) Indigenous status, self-reported and summarized as Indigenous
or non-Indigenous; (e) socioeconomic disadvantage classified using the
Index of Relative Socioeconomic Disadvantage (SEIFA 2006) based on
Statistical Local Areas grouped into quintiles [5]; (f) remoteness of re-
sidence using Statistical Local Areas grouped according to the 2006
Australian Standard Geographical Classification (ASGC) as major cities,
inner regional, outer regional, remote, or very remote [6]; (g) local
health district of residence; and (h) cancer stage (degree of spread)
classified as localized, regional or distant.
Histories of BreastScreen participation were analysed by these de-
scriptors, initially without statistical adjustment using the Pearson’s
chi-square test or Fisher’s Exact test for small numbers [9]. Multivariate
logistic regression analyses were also undertaken, by modelling de-
scriptors as predictors of BreastScreen participation, and among parti-
cipants, of time duration between diagnosis and the last screen as< 24
vs 25+ months [9]. Predictors were expressed as dummy variables
using the first category listed for the respective predictor in Table 1 as
the reference category. Relative odds (i.e., odds ratios) were derived
from these regression analyses. Analyses were conducted using Stata 14
[9].
Approval for the study was obtained from the NSW Population and
Health Services Research Ethics Committee (Cancer Institute sub-study
reference: 2017/UMB1106) and the Aboriginal Health and Medical
Research Ethics Committee (reference: 120/16).
3. Results
3.1. Percentage of women with breast cancer with a history of “ever
screened” by BreastScreen NSW
3.1.1. By age
The percentage with any history of participation varied by age
(p < 0.001) from 23 % for 40−49 years to 68 % for 50–59 years, 78 %
for 60–69 years, and 72 % for 70–74 years (Table 1). Multivariate re-
gression analysis, adjusting for the other characteristics, was con-
firmatory, with the highest relative odds of a history of BreastScreen
participation of 10.66 (95 % CI: 9.70–11.71) where cancers were di-
agnosed at age 60–69 years, 7.14 (95 % CI: 6.52–7.80) for diagnosis at
50–59 years, and 6.34 (95 % CI: 5.60–7.17) for diagnoses at 70–74
years, when compared with 40−49 years as the reference age (Table 2).
3.1.2. By country of birth
Any history of participation history by country of birth (p < 0.001)
from 51 % for Asia and 54 % for Africa (other) to 63 % for Australia and
64 % for Europe (Table 1). Multivariate regression analysis was con-
firmatory, indicating a comparatively high adjusted odds of a screening
history for the Australian born and lower relative odds for: Africa
(other) at 0.73 (95 % CI: 0.53–0.99) and Asia at 0.77 (95 % CI:
0.68–0.88) (Table 2).
3.1.3. By Indigenous status
Indigenous women were less likely to have any history of
BreastScreen NSW screening (56 % vs 62 % for non-Indigenous women,
(p= 0.003) (Table 1), which was confirmed by an adjusted OR of 0.71
(95 % CI: 0.55–0.92) (Table 2).
3.1.4. By geographic remoteness
Any history of participation varied by geographic remoteness of
residence (p < 0.001). The lowest participation of 61 % related to a
major city area and the highest at 67 % for remote (Table 1). The lower
participation for residents of major city areas is supported by the ele-
vated adjusted relative odds of screening participation of 1.30 (95 % CI:
1.15–1.48) for inner regional and 3.60 (95 % CI: 1.87–6.94) for remote
(Table 2).
3.1.5. By socioeconomic status
Variation in any history of participation history by SEIFA Index of
Relative Socioeconomic Disadvantage was statistically significant
(p < 0.001) (Table 1). Compared with the most disadvantaged quintile
of geographic areas, the lowest adjusted relative odds of BreastScreen
participation of 0.85 (95 % CI: 0.75–0.97) applied to the next most
disadvantaged quintile (Table 2).
3.1.6. By local health district
Any history of participation varied by local health district
(p < 0.001), ranging from 57 % for South West Sydney to 71 % for
Hunter North East (Table 1). Albury, which abuts the Victorian border
where optional Victorian screening services exist, had the lowest ad-
justed relative odds of 0.63 (95 % CI: 0.40–0.98) of screening through
BreastScreen NSW when compared with the Sydney Local Health Dis-
trict (LHD) reference. By comparison, elevated relative odds applied to
Hunter North East at 1.33 (95 % CI: 1.11–1.60) and Illawarra/Shoal-
haven at 1.26 (95 % CI: 1.02–1.57) (Table 2).
3.1.7. By diagnostic period
History of any BreastScreen participation did not vary significantly
by diagnostic epoch at 62 % both for 2005–2009 and 2010–2014
(Table 1), nor was a difference found in the adjusted analysis (Table 2).
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3.1.8. By stage
Any history of BreastScreen participation varied by stage
(p < 0.001), with earlier stage applying where women had partici-
pated. A history of this participation applied to 69 % of women with
localized cancer, 57 % of those with regional cancer, and 43 % of those
with more advanced cancers (Table 1). Compared with localized
cancer, the adjusted relative odds of BreastScreen participation for re-
gional breast cancers was 0.63 (95 % CI: 0.59–0.68) and for distant
spread, 0.30 (95 % CI: 0.26–0.34) (Table 2).
3.2. For women with breast cancer with a history of “ever screened” through
BreastScreen NSW, the proportion last screened< 24 months prior to
diagnosis
3.2.1. By age
The proportion of women of all ages diagnosed with breast cancer
who had been screened< 24 months was 48 % (Table 1). They re-
presented 77 % of all those with breast cancer who had a history of ever
being screened through BreastScreen NSW (Table 1). The percentage
screened<24 months of the ever screened varied from 54 % for ages
70–74 years to 65 % for 40−49 years, with the percentage
screened<24 months being 82 % for 60–69 years and 83 % for 50–59
Table 1
BreastScreen NSW participation history of women diagnosed with invasive breast cancer: NSW 2005-14* (n=35192).
Characteristic % never screened
(n=13391)
% screened 25+ months previously
(n= 4968)
% screened ≤ 24 months previously
(n= 16833)
3-group difference
P value**
Age (years): <0.001
40–49 (n= 7870) 76.8 8.1 15.1
50–59 (n= 11388) 31.7 11.7 56.6
60–69 (n= 12038) 22.0 14.1 63.9
70–74 (n= 3896) 27.9 33.4 38.7
Country of birth: <0.001
Australia (n= 13322) 37.2 14.3 48.6
Europe (n= 3099) 36.3 14.6 49.1
North Africa/ Middle East (n= 556) 43.4 11.9 44.8
Asia (n= 1450) 49.2 11.3 39.5
Americas (n=318) 41.8 15.4 42.8
Africa (other) (n= 211) 46.0 13.7 40.3
(Unknown (n=615))
15617 unrecorded
(43.5) (13.3) (47.5)
Indigenous status identifier: 0.003
Non-Indigenous (n= 34592) 38.0 14.1 48.0
Indigenous (n= 600) 43.7 15.3 41.0
Residential location: <0.001
Major city (n= 24736) 39.1 14.4 46.5
Inner regional (n=7935) 35.2 13.5 51.3
Outer regional (n= 2356) 37.6 13.3 49.1
Remote (n= 141) 23.4 13.5 63.1
Very remote (n= 21) 33.3 19.1 47.6
(Unknown (n=3)) (100)
SEIFA IRD: <0.001
Most disadvantage (n=6125) 37.8 14.0 48.2
More disadvantage (n= 7157) 37.0 13.6 49.4
Mid disadvantage (n= 6976) 36.5 14.4 49.1
Less disadvantage (n= 6841) 40.4 13.9 45.7
Least disadvantage (n= 8090) 39.5 14.5 46.9
(Unknown (n=3))
Diagnosis period: 0.437
2005–09 (n=16035) 38.4 14.2 47.5
2010–14 (n=19175) 37.8 14.1 48.1
Local health district: <0.001
Sydney (n=2353) 41.1 16.3 42.6
South West Sydney (n= 3534) 42.6 13.7 43.7
South East Sydney (n= 4027) 37.5 14.0 48.5
Illawarra/Shoal (n= 1960) 31.6 12.6 55.9
West Sydney (n= 3431) 41.0 13.9 45.1
Nepean Blue Mountains (n= 1695) 40.4 14.0 45.6
North Sydney (n= 4812) 38.9 14.2 46.9
Central Coast (n= 1827) 37.0 15.4 47.7
Hunter North East (n= 4647) 29.0 16.9 54.1
North Valley NSW (n=1727) 37.2 12.9 49.9
Mid North NSW (n=1185) 32.9 13.1 54.0
Murrumbidgee (n= 1219) 38.9 12.6 48.6
West NSW (n=1371) 31.1 12.1 56.8
Far West (n= 164) 38.4 15.2 46.3
Albury (n=248) 40.3 13.7 46.0
Stage of cancer: <0.001
Localized (n= 18785) 31.0 13.4 55.5
Regional (n= 13201) 43.4 14.9 41.8
Distant (n= 2082) 56.9 15.9 27.3
NSW: New South Wales; IRD: Index of Relative Disadvantage; SEIFA: Socio-Economic Indexes for Areas.
* Excludes missing values; excludes South NSW as records split with BreastScreen ACT.
** P value derived from Pearson Chi-square test or Fisher’s exact test (see “2. Methods").
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years (p < 0.001) (Table 1). Multivariate regression analysis, adjusting
for the other characteristics in Table 3, also indicated little difference
between ages 50–59 and 60–69 years in the adjusted relative odds of
being screened< 24 months among those ever screened at 3.49 (95 %
CI: 3.01–4.03) and 3.58 (95 % CI: 3.09–4.13) respectively when com-
pared with the 40−49 year reference, but the adjusted relative odds of
being screened< 24 months among those ever screened was lower at
0.66 (95 % CI: 0.56–0.77) for 70–74 years compared with the 40–49-
year reference (Table 3).
3.2.2. By country of birth
Variations in the percentage of ever screened women last
screened<24 months of diagnosis approached but did not achieve
statistical significance by country of birth (p=0.755), ranging between
74 % and 79 % (Table 1). Multivariate regression analysis indicated the
relative odds of being screened< 24 months among the ever screened
born in the Americas was 0.70 (95 % CI: 0.49–0.99) when compared
with Australia as the reference category (Table 3).
Table 2
Relative odds (95 % CI) of a BreastScreen history for women diagnosed with
invasive breast cancer (n= 35192); NSW 2005–14.*
Characteristic Unadjusted relative
odds
Adjusted** relative
odds
Age (years):
40–49 (n= 7870) 1.00 1.00
50–59 (n= 11388) 7.10 (6.65–7.59) 7.14 (6.52–7.80)
60–69 (n= 12038) 11.70 (10.93–12.52) 10.66 (9.70–11.71)
70–74 (n= 3896) 8.56 (7.84–9.34) 6.34 (5.60–7.17)
Country of birth:
Australia (n= 13322) 1.00 1.00
Europe (n= 3099) 1.04 (0.96–1.13) 0.93 (0.84–1.02)
North Africa/ Middle East
(n= 556)
0.77 (0.65–0.92) 0.86 (0.70–1.05)
Asia (n= 1450) 0.61 (0.55–0.68) 0.77 (0.68–0.88)
Americas (n=318) 0.82 (0.66–1.03) 0.78 (0.60–1.01)
Africa (other) (n= 211) 0.70 (0.53–0.91) 0.73 (0.53–0.99)
Indigenous status identifier:
Non-Indigenous (n= 34592) 1.00 1.00
Indigenous (n= 600) 0.79 (0.67–0.93) 0.71 (0.55–0.92)
Residential location:
Major city (n= 24736) 1.00 1.00
Inner regional (n=7935) 1.18 (1.12–1.24) 1.30 (1.15–1.48)
Outer regional (n= 2356) 1.07 (0.98–1.16) 1.16 (0.95–1.43)
Remote (n= 141) 2.10 (1.42–3.10) 3.60 (1.87–6.94)
Very remote (n= 21) 1.28 (0.52–3.18) 0.41 (0.10–1.62)
SEIFA IRD:
Most disadvantage (n=6125) 1.00 1.00
More disadvantage (n= 7157) 1.03 (0.97–1.11) 0.85 (0.75–0.97)
Mid disadvantage (n= 6976) 1.06 (0.99–1.14) 1.00 (0.88–1.14)
Less disadvantage (n= 6841) 0.90 (0.84–0.96) 1.02 (0.90–1.16)
Least disadvantage (n= 8090) 0.97 (0.91–1.04) 1.12 (0.96–1.30)
Diagnosis period:
2005–09 (n=16035) 1.00 1.00
2010–14 (n=19175) 1.02 (0.98–1.07) 0.95 (0.87–1.04)
Local health district:
Sydney (n=2353) 1.00 1.00
South West Sydney (n= 3534) 0.94 (0.84–1.05) 0.84 (0.71–1.00)
South East Sydney (n= 4027) 1.17 (1.05–1.29) 1.10 (0.93–1.30)
Illawarra/Shoal (n= 1960) 1.51 (1.33–1.71) 1.26 (1.02–1.57)
West Sydney (n= 3431) 1.00 (0.90–1.12) 1.00 (0.84–1.18)
Nepean Blue Mountains
(n= 1695)
1.03 (0.91–1.17) 0.77 (0.63–0.94)
North Sydney (n= 4812) 1.10 (0.99–1.21) 0.93 (0.78–1.11)
Central Coast (n= 1827) 1.19 (1.05–1.35) 1.01 (0.83–1.24)
Hunter Valley North East
(n= 4647)
1.71 (1.54–1.89) 1.33 (1.11–1.60)
North NSW (n=1727) 1.18 (1.04–1.34) 0.89 (0.71–1.13)
Mid North NSW (n=1185) 1.42 (1.23–1.65) 0.95 (0.72–1.25)
Murrumbidgee (n= 1219) 1.10 (0.95–1.26) 0.74 (0.56–0.97)
West NSW (n=1371) 1.55 (1.34–1.78) 0.97 (0.75–1.27)
Far West (n= 164) 1.12 (0.81–1.55) 0.67 (0.39–1.14)
Albury (n=248) 1.03 (0.79–1.35) 0.63 (0.40–0.98)
Stage of cancer:
Localized (n= 18785) 1.00 1.00
Regional (n= 13201) 0.59 (0.56–0.62) 0.63 (0.59–0.68)
Distant (n= 2082) 0.34 (0.31–0.37) 0.30 (0.26–0.34)
NSW: New South Wales; CI: Confidence Interval; IRD: Index of Relative
Disadvantage; SEIFA: Socio-Economic Indexes for Areas.
* Excludes Southern NSW as records split with BreastScreen ACT.
** Derived from multivariate logistic regression (see “2. Methods”).
Table 3
Relative odds (95 % CI) of a recent BreastScreen history (≤24months) com-
pared with an earlier Breast history (25+months) for women diagnosed with
invasive breast cancer (n=21801); NSW 2005–14.*
Characteristic Unadjusted relative
odds
Adjusted relative
odds**
Age (years):
40– 49 (n= 1829) 1.00 1.00
50–59 (n= 7774) 2.61 (2.32–2.92) 3.49 (3.01–4.03)
60–69 (n= 9387) 2.44 (2.19–2.73) 3.58 (3.09–4.13)
70–74 (n= 2811) 0.62 (0.55–0.70) 0.66 (0.56–0.77)
Country of birth:
Australia (n= 8368) 1.00 1.00
Europe (n= 1974) 0.99 (0.88–1.11) 0.97 (0.85–1.11)
North Africa/ Middle East
(n=315)
1.11 (0.84–1.46) 1.07 (0.79–1.44)
Asia (n= 738) 1.02 (0.86–1.23) 1.04 (0.85–1.27)
Americas (n= 185) 0.81 (0.59–1.13) 0.70 (0.49–0.99)
Africa (other) (n=114) 0.86 (0.56–1.32) 0.75 (0.48–1.18)
Indigenous status identifier:
Non-Indigenous (n=21463) 1.00 1.00
Indigenous (n=338) 0.79 (0.62–1.00) 0.54 (0.38–0.78)
Residential location:
Major city (n= 15068) 1.00 1.00
Inner regional (n= 5140) 1.17 (1.08–1.27) 1.13 (0.96–1.33)
Outer regional (n= 1471) 1.14 (1.00–1.30) 1.06 (0.81–1.39)
Remote (n=108) 1.45 (0.88–2.38) 1.41 (0.68–2.94)
Very remote (n=14) 0.77 (0.24–2.47) NA
SEIFA IRD:
Most disadvantaged (n= 3809) 1.00 1.00
More disadvantaged (n= 4511) 1.06 (0.95–1.17) 0.86 (0.73–1.03)
Mid disadvantaged (n= 4431) 1.00 (0.90–1.11) 0.91 (0.77–1.08)
Less disadvantaged (n=4078) 0.96 (0.86–1.06) 0.90 (0.75–1.08)
Least disadvantaged (n= 4972) 0.94 (0.85–1.04) 0.85 (0.69–1.05)
Diagnosis period:
2005–09 (n= 9881) 1.00 1.00
2010–14 (n= 11920) 1.02 (0.96–1.09) 1.06 (0.94–1.20)
Local health district:
Sydney (n= 1386) 1.00 1.00
South West Sydney (n=2029) 1.22 (1.04–1.42) 1.06 (0.84–1.34)
South East Sydney (n=2519) 1.32 (1.14–1.53) 1.51 (1.21–1.87)
Illawarra/Shoal (n= 1341) 1.70 (1.42–2.04) 2.09 (1.55–2.81)
West Sydney (n=2025) 1.24 (1.06–1.44) 1.21 (0.96–1.52)
Nepean Blue Mountains
(n=1010)
1.24 (1.03–1.49) 1.10 (0.83–1.45)
North Sydney (n= 2942) 1.26 (1.09–1.46) 1.41 (1.12–1.78)
Central Coast (n= 1152) 1.18 (0.99–1.42) 1.22 (0.93–1.60)
Hunter Valley North East
(n=3298)
1.22 (1.06–1.41) 1.04 (0.82–1.32)
North NSW (n=1084) 1.47 (1.22–1.78) 1.30 (0.95–1.79)
Mid North NSW (n=795) 1.58 (1.28–1.95) 1.32 (0.92–1.90)
Murrumbidgee (n=745) 1.48 (1.19–1.83) 1.37 (0.95–1.98)
West NSW (n=945) 1.79 (1.46–2.20) 1.74 (1.21–2.49)
Far West (n=101) 1.16 (0.73–1.85) 0.55 (0.28–1.08)
Albury (n= 148) 1.28 (0.86–2.95) 1.44 (0.72–2.85)
Stage of cancer:
Localized (n= 12955) 1.00 1.00
Regional (n= 7476) 0.68 (0.64–0.73) 0.70 (0.63–0.77)
Distant (n= 898) 0.41 (0.36–0.48) 0.49 (0.40–0.60)
NSW: New South Wales; CI: Confidence Interval; IRD: Index of Relative
Disadvantage; NA: non-applicable due to small numbers; SEIFA: Socio-
Economic Indexes for Areas.
* Excludes Southern NSW as records split with BreastScreen ACT.
** Derived from multivariate logistic regression (see “2. Methods”).
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3.2.3. By indigenous status
Screening participation<24 months of diagnosis among the ever
screened was 73 % for Indigenous women, which was a lower than the
corresponding 77 % for non-Indigenous women (p=0.050) (Table 1).
The adjusted relative odds of screening participation<24 months
among the ever screened was 0.54 (95 % CI: 0.38–0.78) for Indigenous
compared with non-Indigenous women (Table 3).
3.2.4. By geographic remoteness
Participation<24 months of diagnosis among the ever screened
also varied by geographic remoteness (p < 0.001). A lower participa-
tion suggested for major city. Also, a low participation for< 24 months
of diagnosis of 71 % presented among the ever screened for very remote
areas, but this was based on a very small numbers (n= 14) (Table 1).
Confidence intervals for the adjusted relative odds of screening parti-
cipation<24 months among the ever screened in each region over-
lapped the reference of 1.00 for major city areas, indicating that dif-
ferences were potentially due to chance (Table 3).
3.2.5. By socioeconomic status
The variation in participation<24 months among the ever
screened by SEIFA Index of Relative Socioeconomic Disadvantage was
small, with a range of 76–78 %, and was not statistically significant
(p=0.117). Similarly, adjusted relative odds did not point to differ-
ences by socioeconomic status (Table 3).
3.2.6. By local health district
BreastScreen NSW participation<24 months among the ever
screened also varied by local health district (p < 0.001), ranging from
72 % for Sydney LHD to 82 % for Western NSW and Illawarra/
Shoalhaven LHDs (Table 1). Compared with Sydney LHD, higher re-
lative odds generally applying for other LHDs, with the highest pre-
senting for Illawarra/Shoalhaven at 2.09 (95 % CI: 1.55–2.81), Western
NSW at 1.74 (95 % CI: 1.21–2.49), South East Sydney LHD at 1.51 (95
% CI: 95 % 1.21–1.87) and North Sydney 1.41 (1.12–1.78) (Table 3).
3.2.7. By diagnostic period
Participation did not vary by diagnostic period (p= 0.548) with
participation<24 months among the ever screened approximating 77
% for both 2005–2009 and 2010–2014 (Table 1). The adjusted relative
odds of participation were 1.06 (95 % CI: 0.94–1.20) for 2010–2014
compared with 2005–2009 (Table 3).
3.2.8. By stage
Participation<24 months among the ever screened was higher for
localized tumours at 81 % compared with 74 % for regional cancers and
63 % for distant spread (p < 0.001) (Table 1). The adjusted relative
odds of participation< 24 months among the ever screened were 0.70
(95 % CI: 0.63–0.77) for regional cancers and 0.49 (95 % CI: 0.40–0.60)
for distant spread compared with localized tumours (Table 3).
4. Discussion
Approximately 73 % of NSW women aged 50–69 years at diagnosis
of invasive breast lesions in 2005–14 had previously participated in the
BreastScreen NSW screening program, and 72 % of those aged 70–74
years had done so. Meanwhile the percentage of women aged
40−49 years who had participated was much lower at 23 %. This dif-
ference is understandable. While these younger women were eligible
for screening, they were not included in the principal screening target
age range prior to 2014 and were not actively recruited for screening.
Data were not available to us on reasons women may choose to be
or not to be screened. The study is therefore limited to describing
screening history as such, although some factors that may have con-
tributed to decisions on screening participation are suggested. In par-
ticular, the study is limited to describing screening histories in those
women who went on to be diagnosed with breast cancer.
We consider that these data, by relating to women diagnosed with
breast cancer, are complementary to population-based data. Among
those diagnosed women would be some at elevated risk of breast cancer
mortality. Those with a history of BreastScreen NSW participation in-
cluded women with screen-detected and interval cancers, and others
whose cancers were found at a later time. History of screening within
24 months of diagnosis can better be used for comparison with
screening policy.
The national accreditation standard is 70 % for women aged 50–69
years to be screened during a 24-month period with intervals between
screening rounds up to 27 months allowed in national accreditation and
reporting [1] While the percentage of breast cancer patients recorded
on the NSW Cancer Registry at this age who reported a history of
screening within the 24 months of diagnosis was lower at 60 %, it ex-
ceeded the 53 % generally observed at a population level for this age
range [2,10]. This may reflect a greater participation in screening of
higher risk women, such as: (1) the Australian rather than overseas
born [10]; and (2) those high-risk women encouraged to screen due to
family history of breast cancer, use of hormone replacement therapy or
personal history of benign breast disease [1,3]. In addition, differences
in lead time and overdiagnosis are likely contributors.
The percentage of women diagnosed with invasive breast cancer at
age 70–74 years, who had a screening history within 24 months prior to
diagnosis, was lower at 39 %. Again, this is understandable as these
women were not included in the screening target age range prior to
2014. Further monitoring will indicate whether their 24-month
screening participation increases following the extension of the
screening target age range to include them and the more active pro-
motion of screening that has now occurred for this age range. Women
aged 75 years or more, while not targeted for screening, should be in-
cluded in future monitoring activity, given the important questions
around net harms and benefit, especially as life expectancies and dis-
ability-free life expectancies improve.
A history of BreastScreen NSW participation within 24 months of
diagnosis was generally not lower across more remote residential areas,
which is reassuring. Indeed, this screening history experience was
higher at 61 % for remote and very remote populations than the 48 %
for less remote locations (p < 0.001). We attribute this difference, at
least in part, to the emphasis given in the screening program to
reaching remote country communities through mobile facilities.
Women with breast cancer who were born in Australia were more
likely to have participated through BreastScreen NSW than other
women, with lower participation most evident for women born in Asia
and Africa (other than North Africa). The reasons are not known but
could include cultural factors and language difficulties encountered by
some Asian and African women. Further research is needed to identify
the sub-populations and barriers involved such that more effective
screening promotion can be designed.
Major city residents with breast cancer were less likely to have a
BreastScreen NSW history after adjusting for confounders, with
stronger screening histories indicated in particular for residents of inner
regional and remote areas. This difference is consistent with the lower
participation frequently reported at a population level in Australian
screening monitoring reports [1,10,11]. The reasons are unclear as
screening services are available throughout major cities in NSW. Fur-
ther research is needed to identify barriers, including whether geo-
graphic differences in culture are involved, and availability of private
de facto screening options.
Indigenous women with breast cancer were less likely than non-
Indigenous women to have a history of participation in BreastScreen
NSW and to be less likely to have participated within the 24 months
preceding diagnosis. Further initiatives should be directed at screening
promotion among Indigenous women, given their poorer survival out-
comes following breast-cancer diagnosis [12]. By comparison, the lack
of a gradient in history of screening participation by socioeconomic
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status is reassuring, although this observation was based on residential
SLAs where potential for masking, given differing population numbers
and geographic sizes exist.
Women diagnosed with advanced metastatic breast cancers were
less likely to have a history of breast screening, with 27 % being
screened in the 24 months preceding diagnosis compared with 42 % for
those with regional spread and 56 % for those with localized cancer.
This pattern was expected and is interpreted as a validation of the
measure of breast screening used in this study.
Compared with Sydney LHD as the reference category, the adjusted
relative odds of having participated in BreastScreen NSW was lower for
women diagnosed with breast cancer from Nepean Blue Mountains,
Murrumbidgee and Albury LHDs and higher for Illawarra/Shoalhaven
and Hunter North East LHDs. The potential to use interstate services
may contribute to the lower participation in BeastScreen NSW for LHDs
that abut the NSW border (e.g., Murrumbidgee and Albury LHDs) but
the reasons for these differences and lower participation in Nepean Blue
Mountains and higher participation for Illawarra/Shoalhaven and
Hunter North East LHDs warrant further investigation.
Among screened women, the odds of being screened within 24
months of diagnosis were lower for the 70–74-year age range than for
younger women. This probably reflects their non-inclusion in the
principal screening target age range until 2014. Previously they were
able to gain access to screening but they were not actively invited.
Screened women with lower odds of being screened within 24 months
of diagnosis also included Indigenous women. Further investigation
into the reasons for this result is important, including any aspect of the
screening experience that may have acted as a barrier.
5. Conclusions
Of NSW women aged 50–69 years who had been diagnosed with
breast cancer, about 73 % had previously participated in BreastScreen
NSW and about 60 % had participated in BreastScreen NSW in the 24
months preceding diagnosis. This is less than the 70 % target for bi-
ennial screening coverage at a population level, but this target has
never been reached by an Australian jurisdiction.
About 39 % of women aged 70–74 years, who had been diagnosed
with breast cancer, had been screened through BreastScreen NSW in the
24-month period immediately preceding diagnosis. With extension of
the principal screening to cover this age group from 2014, increased
promotion of screening participation is indicated for this age group.
Breast screening participation was lower in Indigenous than non-
Indigenous women in both unadjusted and adjusted analyses. This
underscores the need for further attention to screening participation in
Indigenous women.
While differences in screening participation existed by country of
birth and residential location, pronounced differences were not evident
by socioeconomic status. Qualitative research of screening barriers and
opportunities may provide a useful guide for public education and may
reduce sociodemographic differences in screening history.
This study demonstrates the value of data linkage for determining
screening coverage among women at highest risk of breast cancer, as
testified by their subsequent diagnosis of invasive breast cancer.
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